Home    中文 | English


  • 1998

    Registered in Tai-Chung City with capital of NT$2 millions.

  • 2000

    Moved to Taipei Chong shan N. Road office and increased capital to NT$18 millions. Entered co-developed agreement with Genovate Biotechnology. Entered distribution agreement with Dupont Pharmaceuticals.

  • 2001

    Entered distribution agreement with 3M Pharmaceuticals. Increased capital to NT$22 millions.

  • 2003

    Signed exclusive distribution agreement with Biogen Idec, a US company for conducting the first biologics clinical trial.

  • 2004

    Changed ownership to Limited Company with the same capital size.

  • 2005

    Signed exclusive distribution agreement with Vitrolife,a Swedish company for its lung transplant preservative.

  • 2007

    Acquired Apex Pharma and increase capital size to NT$100M.

  • 2008

    Distributed SAM Medical Products for emergency care.

  • 2009

    Distribute 3 River Pharmaceuticals long acting Amphotericin.

  • 2010

    Entered co-developing agreement with Raptor Therapeutics to conduct Convivia phase II b trial for future marketing and OEM.

  • 2011

    Entered exclusive agreement with AMDL Diagnostics Inc. for DR-70® tumor marker ELISA test for Taiwan.

  • 2012

    Entered exclusive agreement with Baxter Healthcare for Anti-adhesion medical device.

  • 2013

    Entered technology transfer agreement with AMDL Inc. to manufacture DR-70® in Taiwan and supply to Asia-Pacific countries.

  • 2014

    Moved to Current Nei-hu office and increased capital to NT$130 millions. Granted DR-70® Taiwan manufacturing license. Entered distribution agreement with iStat for its Cervi-M DNA Methylation test for Cervical Cancer. Increased capital to NT$170 millions. First export Taiwan version DR-70 to India.

  • 2015

    Received Taiwan FDA approval for DR-70 stability as 18 months.

    Received Taiwan FDA award as Good Distribution Practice company.

    Certified by TRACE and received clearance of anti bribery Compliance Solutions.

    Received Taiwan FDA marketing approval for EZ Detect FOB test.

  • 2016

    Received ISO13495:2003 Medical Device Certification by SGS.

    Establishing Uni Pharma in-house laboratory for new neurological bio-markers R&D and anti-cancer drug blood concentration monitoring test.